Voting Rights and Shares Capital of the Company
Rhea-AI Summary
Nanobiotix (NBTX) has released its latest voting rights and shares capital statement as of December 31, 2024. The company reports 47,426,851 shares outstanding, with 49,204,910 theoretical voting rights and 49,182,792 exercisable voting rights.
Nanobiotix is a late-stage clinical biotechnology company listed on both Euronext Paris and Nasdaq Global Select Market. The company focuses on physics-based therapeutic approaches and owns more than 25 patent families across three nanotechnology platforms: oncology, bioavailability and biodistribution, and disorders of the central nervous system.
Positive
- Owns portfolio of over 25 patent families across three nanotechnology platforms
- Dual-listed on major exchanges (Euronext Paris and Nasdaq)
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, NBTX declined 1.05%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
PARIS, Jan. 09, 2025 (GLOBE NEWSWIRE) --
Paris, France, January 9, 2025
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com
| Date | Number of Shares Outstanding | Total number of voting rights | |
| Total voting rights, theoretical1 | Total voting rights, exercisable2 | ||
| December 31, 2024 | 47,426,851 | 49,204,910 | 49,182,792 |
About NANOBIOTIX
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.
Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.
Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.
For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.
Contacts
| Nanobiotix | |
Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com | Investor Relations Department Craig West SVP, Investor Relations +1 (617) 583-0211 investors@nanobiotix.com |
________________________________
1 The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.
2 The total number of exercisable at a shareholders’ meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed.
Attachment
- 2025-01-09 -- NBTX -- Voting Rights & Shares Capital -- FINAL
FAQ
How many shares does Nanobiotix (NBTX) have outstanding as of December 31, 2024?
What is the difference between NBTX theoretical and exercisable voting rights?
How many patent families does Nanobiotix (NBTX) own?
On which stock exchanges is Nanobiotix (NBTX) listed?
